(IZAFE-B) iZafe Series - Ratings and Ratios

iZafe Group AB (publ), a Swedish medical technology company, specializes in developing and marketing digital health solutions aimed at improving medication adherence and safety. The companys product portfolio includes Dosell, an automated medication dispenser designed to simplify drug management for patients, and Pilloxa, a digital platform that provides real-time monitoring and data-driven insights to enhance patient engagement and adherence. iZafe Group AB (publ) was established in 2008 and is headquartered in Stockholm, Sweden. The company rebranded from MediRätt AB (publ) to iZafe Group AB (publ) in May 2019, reflecting its expanded focus on innovative digital health solutions. Web URL: https://www.izafe.se

ticker Symbol: IZAFE-B exchange: ST type: common stock country Origin: Sweden gics Sub Industry: Life Sciences Tools & Services

Based on the provided and , the 3-month forecast for iZafe Group AB Series B (ST:IZAFE-B) indicates potential stability with limited upside. The stock is currently trading at 0.25 SEK, with SMA 20 and SMA 50 at 0.25 and 0.23, respectively, suggesting a sideways trend. The ATR of 0.02 reflects low volatility, indicating minimal price fluctuations. On the fundamental side, the high P/B ratio of 8.86 and P/S ratio of 10.84 suggest a premium valuation relative to book value and sales. With a market cap of 86.23M SEK, the stock may face challenges in near-term growth without significant catalysts. Investors should monitor earnings reports and operational updates for potential shifts in momentum.